Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT01336907

Comparison Between Home Macular Perimeter and Optical Coherence Tomography (OCT) Visual Field Defects in Patients With Choroidal Neovascularization (CNV)

Comparison Between Home Macular Perimeter and OCT Visual Field Defects in Patients With CNV

Status
Withdrawn
Phase
Study type
Observational
Enrollment
0 (actual)
Sponsor
Notal Vision Ltd. · Industry
Sex
All
Age
55 Years
Healthy volunteers
Not accepted

Summary

The FORESEE HOME is intended for the early detection of central and paracentral irregularities (abnormalities) in the visual field, most commonly associated with Age Related Macular Degeneration (AMD). However, the device has the ability to detect the development of the lesion post treatment and therefore to assess in determination of the next treatment. The Optical Coherence Tomography (OCT) may be used as well to identify choroidal neovascularization (CNV). Comparison between the two methods will allow better understanding of both devices. The FORESEE HOME can be used as an assessment tool for the progression and success of the treatment given to AMD lesions. Therefore, evaluating the size and the location of the treated lesions may serve as an additional tool.

Conditions

Timeline

First posted
2011-04-18
Last updated
2016-09-21

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT01336907. Inclusion in this directory is not an endorsement.

Comparison Between Home Macular Perimeter and Optical Coherence Tomography (OCT) Visual Field Defects in Patients With C (NCT01336907) · Clinical Trials Directory